Mintz Life Sciences Deal Activity (October – December 2021)

Mergers & Acquisitions

  • Represented Hyperfine, Inc. (NASDAQ:HYPR), a medical device company that created a portable MRI system, in its $580M business combination with Liminal Sciences, Inc. and the SPAC, HealthCor Catalio Acquisition Corp. (December 2021)
  • Represented Chromaderm, a clinical-stage biotechnology company developing a topical inhibitor of melanin production, in its sale to DermBiont, a clinical-stage biotechnology company developing targeted topical therapeutics (December 2021)

Venture Capital

  • Investor-side representation in a Series Seed financing of Fisher Wallace, a manufacturer of a FDA-Approved wearable cranial electrotherapy neurostimulation device to treat depression, anxiety and insomnia by SHUFL Capital (December 2021)
  • Represented Radicle Science, Inc., a healthtech company, in a Series Seed financing (November 2021)
  • Represented Cardurion Pharmaceuticals, Inc., a clinical-stage biotechnology company, in a private investment of up to $300M from Bain Capital Life Sciences and Bain Capital Private Equity (November 2021)
  • Represented Teal Bio, an MIT spinout that’s building reusable silicone anti-viral respirators, in a preferred stock financing (November 2021)
  • Represented Hopewell Therapeutics in a Series Seed financing (October 2021)

Licensing & Collaborations

  • Represented BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) in its option, collaboration, and license agreement with pharmaceutical company Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan (December 2021)
    • Under the terms of the agreement, BeiGene will receive an upfront cash payment of $300M from Novartis along with an additional payment of $600M or $700M upon exercise by Novartis of an exclusive time-based option, subject to receipt of required antitrust approval

Capital Markets

Represented the issuer:

  • Represented Evofem Biosciences, Inc. in its 10M registered direct offering with Keystone Capital Partners acting as the placement agent (October 2021)

Represented the underwriters:

  • Represented the underwriters in the $87.5M public offering of Adicet Bio, Inc. underwritten by Jefferies LLC, Guggenheim Securities, LLC, Truist Securities, Inc., BTIG, LLC, H.C. Wainwright & Co., LLC and JonesTrading Institutional Services, LLC (December 2021)
  • Represented the underwriters in the $172.5M initial public offering (IPO) of ALSP Orchid Acquisition Corporation I underwritten by Stifel, Nicolaus & Company, Incorporated and Nomura Securities International, Inc. (December 2021)
  • Represented the underwriters in the $24M public offering of Evaxion Biotech A/S underwritten by Oppenheimer & Co. Inc., Ladenburg Thalmann & Co. Inc. and Lake Street Capital Markets, LLC (November 2021)
  • Represented the underwriters in the $75M public offering of ANI Pharmaceuticals, Inc. underwritten by Guggenheim Securities, LLC, Raymond James Financial, Inc. and H.C. Wainwright & Co., LLC (November 2021)
  • Represented the underwriters in the $125M public offering of Compass Therapeutics, Inc. underwritten by SVB Leerink LLC, Raymond James & Associates, Inc., Wedbush Securities Inc., H.C. Wainwright & Co., LLC,  The Benchmark Company, LLC and Roth Capital Partners, LLC (November 2021)
  • Represented the underwriters in the $27.5M Regulation A initial public offering (IPO) of AeroClean Technologies, Inc. underwritten by The Benchmark Company, LLC, HCFP/Capital Markets LLC,and Valuable Capital Limited (November 2021)
  • Represented the underwriters in the $50M public offering of ADMA Biologics, Inc. underwritten by Raymond James & Associates, Inc. and Cantor Fitzgerald & Co. (October 2021)
  • Represented the underwriters in the $39.2M public offering of Rezolute, Inc. underwritten by Oppenheimer & Co. Inc. and Roth Capital Partners, LLC (October 2021)
  • Represented the underwriters in the $12M public offering of XORTX Therapeutics Inc. underwritten by Alliance Global Partners (October 2021)
  • Represented the underwriters in the $40.25M public offering of UpHealth, Inc. underwritten by Oppenheimer & Co. Inc., Lake Street Capital Markets, LLC and Northland Securities, Inc. (October 2021)

Represented the sales agent / placement agent:

  • Represented the sales agent in the $50M at-the-market offering of Allena Pharmaceuticals, Inc. with B. Riley Securities, Inc. acting as sales agent (December 2021)
  • Represented the sales agent in the $125M at-the-market offering of Frequency Therapeutics, Inc. with Oppenheimer & Co. Inc. acting as sales agent (December 2021)
  • Represented the sales agent in the $11M at-the-market offering of Strata Skin Sciences, Inc. with Ladenburg Thalmann & Co. Inc. acting as sales agent (October 2021)

View Deal Activity from April – June 2020

View Deal Activity from July – September 2020

View Deal Activity from October – December 2020

View Deal Activity from January – March 2021

View Deal Activity from April 2021 – June 2021

View Deal Activity from July– September 2021 

 

Subscribe To Viewpoints

Published